Hematopoietic and Lymphatic System Neoplasm

cancer family

Identifier: CI-CAN-00000022
Entity page: /cancer/hematopoietic-and-lymphatic-system-neoplasm ↗
Edges: 11,190

Neighbours: 15 genes26 drugs10 trials
Drawn: 51 of 51 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Hematopoietic and Lymphatic System Neoplasm approved for …APPROVED_FORderived15 of 115show all (up to 200)
← approved for	Ruxolitinibsmall molecule FDA (US) · approved · 2026-05-01 · polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea.	—	approved	Polycythemia Vera	1	Regulatory	openfda	graph →
← approved for

Paths

Strongest chains

Gene → variant → drug chains anchored in this cancer (or a descendant), ranked by source-native evidence level then support, with the approval and trial registry hops when they exist.

FLT3 ITD GilteritinibFDA US 2018-11-2826 active / 50 trials
Curatedlevel Asensitivity· support 3civicObservedFLT3 altered in 31% (278 / 903 cases, largest of 8 cohorts)Regulatoryapproved for Acute Myeloid Leukemia (2 approval records)context: Acute Myeloid Leukemia
ALK Fusion CrizotinibFDA US 2011-08-267 active / 8 trials
Curatedlevel Asensitivity· support 3civicObservedcohort frequency not yet available for ALK in this cancerRegulatoryapproved for Anaplastic Large Cell Lymphoma (4 approval records)context: Anaplastic Large Cell Lymphoma
PDGFRA Fusion Imatinib3 active / 26 trials
Curatedlevel Asensitivity· support 3civicObservedcohort frequency not yet available for PDGFRA in this cancerno approval record in this cancercontext: Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions
IDH2 Mutation EnasidenibFDA US 2017-08-0113 active / 24 trials
Curatedlevel Asensitivity· support 2civicObservedIDH2 altered in 12% (111 / 903 cases, largest of 6 cohorts)Regulatoryapproved for Acute Myeloid Leukemiacontext: Acute Myeloid Leukemia
FLT3 D835 GilteritinibFDA US 2018-11-2826 active / 50 trials
Curatedlevel Asensitivity· support 1civicObservedFLT3 altered in 31% (278 / 903 cases, largest of 8 cohorts)Regulatoryapproved for Acute Myeloid Leukemia (2 approval records)context: Acute Myeloid Leukemia
FLT3 I836 GilteritinibFDA US 2018-11-2826 active / 50 trials
Curatedlevel Asensitivity· support 1civicObservedFLT3 altered in 31% (278 / 903 cases, largest of 8 cohorts)Regulatoryapproved for Acute Myeloid Leukemia (2 approval records)context: Acute Myeloid Leukemia
FLT3 Mutation MidostaurinFDA US 2017-04-284 active / 35 trials
Curatedlevel Asensitivity· support 1civicObservedFLT3 altered in 31% (278 / 903 cases, largest of 8 cohorts)Regulatoryapproved for Acute Myeloid Leukemia (3 approval records)context: Acute Myeloid Leukemia
IDH1 Mutation IvosidenibFDA US 2018-07-2020 active / 25 trials
Curatedlevel Asensitivity· support 1civicObservedIDH1 altered in 7.9% (71 / 903 cases, largest of 2 cohorts)Regulatoryapproved for Acute Myeloid Leukemiacontext: Acute Myeloid Leukemia

Each hop keeps its own claim category: cohort alteration frequency (observed, cases ≥ 20), CIViC predictive edge (curated, level as stated by CIViC), regulatory approval (authority, jurisdiction, date as published), trial count (registry). A missing hop is shown as missing — never filled in. Not treatment guidance.

Hematopoietic and Lymphatic System Neoplasm altered in cohorts of …ALTERED_INderived15 of 397show all (up to 200)
← altered in cohorts of	IGHV2-70 437 / 961 cases (45 %) · ssm · MMRF-COMMPASS · largest of 2 cohorts	—	—	Multiple Myeloma	2	Observed	gdc	graph →
← altered in cohorts of	DDX3X 124 / 297 cases (42 %) · ssm · mbn_sfu_2023	—	—	B-Cell Non-Hodgkin Lymphoma	1	Observed	cbioportal	graph →
← altered in cohorts of	IGLV3-1 364 / 961 cases (38 %) · ssm · MMRF-COMMPASS · largest of 2 cohorts	—	—	Multiple Myeloma	2	Observed	gdc	graph →
← altered in cohorts of	FLT3 278 / 903 cases (31 %) · ssm · aml_ohsu_2022 · largest of 7 cohorts	—	—	Acute Myeloid Leukemia	7	Observed	cbioportal	graph →
← altered in cohorts of	SHCBP1 73 / 263 cases (28 %) · ssm · CGCI-BLGSP	—	—	Burkitt Lymphoma	1	Observed	gdc	graph →
← altered in cohorts of	NPM1 233 / 903 cases (26 %) · ssm · aml_ohsu_2022 · largest of 7 cohorts	—	—	Acute Myeloid Leukemia	7	Observed	cbioportal	graph →
← altered in cohorts of	VPS35 67 / 263 cases (25 %) · ssm · CGCI-BLGSP	—	—	Burkitt Lymphoma	1	Observed	gdc	graph →
← altered in cohorts of	ORC6 66 / 263 cases (25 %) · ssm · CGCI-BLGSP	—	—	Burkitt Lymphoma	1	Observed	gdc	graph →
← altered in cohorts of	TPTE 66 / 263 cases (25 %) · ssm · CGCI-BLGSP	—	—	Burkitt Lymphoma	1	Observed	gdc	graph →
← altered in cohorts of	IGHV2-70D 238 / 961 cases (25 %) · ssm · MMRF-COMMPASS · largest of 2 cohorts	—	—	Multiple Myeloma	2	Observed	gdc	graph →
← altered in cohorts of	KMT2D 247 / 1,001 cases (25 %) · ssm · dlbcl_duke_2017 · largest of 5 cohorts	—	—	Diffuse Large B-Cell Lymphoma Unclassifiable	5	Observed	cbioportal	graph →
← altered in cohorts of	KRAS 227 / 961 cases (24 %) · ssm · MMRF-COMMPASS · largest of 4 cohorts	—	—	Multiple Myeloma	4	Observed	gdc	graph →
← altered in cohorts of	MYLK3 62 / 263 cases (24 %) · ssm · CGCI-BLGSP	—	—	Burkitt Lymphoma	1	Observed	gdc	graph →
← altered in cohorts of	CNTNAP3B 70 / 297 cases (24 %) · ssm · mbn_sfu_2023	—	—	B-Cell Non-Hodgkin Lymphoma	1	Observed	cbioportal	graph →
← altered in cohorts of	BCL7A 212 / 961 cases (22 %) · ssm · MMRF-COMMPASS · largest of 3 cohorts	—	—	Multiple Myeloma	3	Observed	gdc	graph →

Hematopoietic and Lymphatic System Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 342show all (up to 200)
→ investigated in trials for	Dexamethasonesmall molecule 873 trials (266 active) · roll-up of the cancer and its descendants	—	—	Hematopoietic and Lymphatic System Neoplasm	873	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 852 trials (210 active) · roll-up of the cancer and its descendants	—	—	Hematopoietic and Lymphatic System Neoplasm	852	Observed	clinicaltrials	graph →
→ investigated in trials for	Cytarabinesmall molecule 707 trials (138 active) · roll-up of the cancer and its descendants	—	—	Hematopoietic and Lymphatic System Neoplasm	707	Observed	clinicaltrials	graph →
→ investigated in trials for	Fludarabinesmall molecule 658 trials (153 active) · roll-up of the cancer and its descendants	—	—	Hematopoietic and Lymphatic System Neoplasm	658	Observed	clinicaltrials	graph →
→ investigated in trials for	Lenalidomidesmall molecule 507 trials (157 active) · roll-up of the cancer and its descendants	—	—	Hematopoietic and Lymphatic System Neoplasm	507	Observed	clinicaltrials	graph →
→ investigated in trials for	Bortezomibsmall molecule 450 trials (99 active) · roll-up of the cancer and its descendants	—	—	Hematopoietic and Lymphatic System Neoplasm	450	Observed	clinicaltrials	graph →
→ investigated in trials for	Azacitidinesmall molecule 383 trials (158 active) · roll-up of the cancer and its descendants	—	—	Hematopoietic and Lymphatic System Neoplasm	383	Observed	clinicaltrials	graph →
→ investigated in trials for	Venetoclaxsmall molecule 365 trials (226 active) · roll-up of the cancer and its descendants	—	—	Hematopoietic and Lymphatic System Neoplasm	365	Observed	clinicaltrials	graph →
→ investigated in trials for	Rituximabmonoclonal antibody 329 trials (83 active) · roll-up of the cancer and its descendants	—	—	Hematopoietic and Lymphatic System Neoplasm	329	Observed	clinicaltrials	graph →
→ investigated in trials for	Etoposidesmall molecule 313 trials (53 active) · roll-up of the cancer and its descendants	—	—	Hematopoietic and Lymphatic System Neoplasm	313	Observed	clinicaltrials	graph →
→ investigated in trials for	Melphalansmall molecule 305 trials (51 active) · roll-up of the cancer and its descendants	—	—	Hematopoietic and Lymphatic System Neoplasm	305	Observed	clinicaltrials	graph →
→ investigated in trials for	Methotrexatesmall molecule 303 trials (58 active) · roll-up of the cancer and its descendants	—	—	Hematopoietic and Lymphatic System Neoplasm	303	Observed	clinicaltrials	graph →
→ investigated in trials for	Busulfansmall molecule 256 trials (41 active) · roll-up of the cancer and its descendants	—	—	Hematopoietic and Lymphatic System Neoplasm	256	Observed	clinicaltrials	graph →
→ investigated in trials for	Filgrastimother 248 trials (21 active) · roll-up of the cancer and its descendants	—	—	Hematopoietic and Lymphatic System Neoplasm	248	Observed	clinicaltrials	graph →
→ investigated in trials for	Vincristinesmall molecule 223 trials (65 active) · roll-up of the cancer and its descendants	—	—	Hematopoietic and Lymphatic System Neoplasm	223	Observed	clinicaltrials	graph →

Hematopoietic and Lymphatic System Neoplasm studied in …STUDIED_INderived10 of 10,336show all (up to 200)
→ studied in	NCT00006518recruiting Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer · condition mapped ONTOLOGY_EXACT · 10,336 trials mapped (2,919 active)	—	—	Primary Effusion Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00923507recruiting Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL) · condition mapped ONTOLOGY_EXACT · 10,336 trials mapped (2,919 active)	—	—	Waldenstrom Macroglobulinemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT01676805recruiting Tissue Collection for Studies of Lymph Cancer · condition mapped CURATED_EXACT · 10,336 trials mapped (2,919 active)	—	—	Multiple Myeloma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02473757enrolling by invitation Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies · condition mapped CURATED_EXACT · 10,336 trials mapped (2,919 active)	—	—	Multiple Myeloma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02682667recruiting Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols · condition mapped CURATED_EXACT · 10,336 trials mapped (2,919 active)	—	—	Multiple Myeloma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02767063Phase 1/Phase 2 · active not recruiting Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW) · condition mapped ONTOLOGY_EXACT · 10,336 trials mapped (2,919 active)	—	—	Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT03223610Phase 1/Phase 2 · recruiting Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 10,336 trials mapped (2,919 active)	—	—	Burkitt Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03412877Phase 2 · recruiting Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer · condition mapped CURATED_EXACT · 10,336 trials mapped (2,919 active)	—	—	Multiple Myeloma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03494569Phase 1 · suspended Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome · condition mapped CURATED_BROADER · 10,336 trials mapped (2,919 active)	—	—	Acute Myeloid Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT03560752Phase 1 · active not recruiting CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant · condition mapped ALIAS · 10,336 trials mapped (2,919 active)	—	—	Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive	1	Observed	clinicaltrials	graph →